Skip to content
Subscriber Only

Bayer Stock Rises as New Drugs Propel Revenue Increases

Bayer AG shares rose to a record as stronger-than-predicted demand for new drugs outweighed a drop in plastics revenue that the German manufacturer said makes its full-year sales forecast “ambitious.”

Revenue from products including the Xarelto blood thinner and Eylea eye medicine “are progressing considerably better than expected,” Leverkusen-based Bayer said in a statement today. The company raised its forecast for sales from new drugs to 1.4 billion euros ($1.9 billion euros) from a previous estimate of 1 billion euros.